Medtronic Insulin Pump Therapy – BDF
Medtronic Self-Adjusting Insulin Technology
Better Diabetes Management
Medtronic’s MiniMed™ insulin delivery systems feature SmartGuard™ technology that help you stay in range!1 Your pump takes action when it senses your glucose values going below a preset level, resulting in fewer highs and lows as well as less effort to manage your diabetes. The combination of Medtronic’s pump and Guardian™ sensor system, you’re four times more likely to reach your target A1C, reduce low glucose episodes by up to 84 percent, and lower your risk of long-term complications.2, 3, 4
Pump automatically adjusts background insulin every 5 minutes to help you stay in target range.*
See insulin delivery, sugar trends, and high and low alerts on your smartphone by downloading the app.
No hassle upgrade! The MiniMed 770G is enabled for future software upgrades, when available.
Your insulin pump data can be shared with your healthcare provider, family, and care team for peace of mind.*
MiniMed™ 630G Insulin Pump System
Succeed in managing your diabetes with the Medtronic MiniMed™ 630G™ Insulin Pump System! Featuring SmartGuard™ technology, this system takes action for you if your sensor glucose values go below a preset level. If you don’t respond to alarms, the SmartGuard™ technology can pause insulin delivery for up to two hours – giving you time to recover.
Insulin pump therapy with the MiniMed™ system makes it easier to stay in range. With an optional CGM, the MiniMed™ 630G™ pump connects to the Guardian™ Sensor 3 to continuously check your glucose levels detecting highs and lows, while working SmartGuard™ technology to help you stay in range. The only FDA-approved meter for use with the MiniMed™ 630G™ system is the Contour® Next Link 2.4 Meter, which is designed for easy and accurate CGM calibration, insulin dosing, and remote bolusing.
“Using an insulin pump to manage my diabetes has given me the flexibility to live my best life!”– Carling, Medtronic Insulin Pump Customer
Is An Insulin Pump Right For Me?
Ask your healthcare professional about insulin pump therapy if you:
Have type 1 or type 2 diabetes
Take 3 or more insulin injections per day
Take other medications in addition to insulin to manage your diabetes
Would like to better manage your diabetes
Ready to Get Started with Medtronic Insulin Pump Technology?
At EHCS, our goal is to provide you with a first-rate customer experience through the entire process. After you complete our online Medtronic form, EHCS will pair you with a dedicated Diabetes Care Advisor to help you through the process. From insurance approval and product selection to future reorders, our team of DCAs is your guide to better diabetes control.
* Assumes four injections per day for 30 days and one infusion set change every two to three days.
** Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.
1. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012;55:3155–3162. 2. Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized prospective trial comparing the efficacy of insulin pump therapy with multiple daily injections using insulin glargine. Diabetes Care. 2004;27(7):1554–1558. 3. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19:324–327. 4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. 5. Bailey T, et al. Accuracy, Precision, and User Performance Evaluation of the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System. Poster presented at the 7th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD); 2014 February 5–8, Vienna, Austria.
Important Safety Information: MiniMed™ 770G System With SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide Test Strips. The system requires a prescription.The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than eight units or more than 250 units of total daily insulin per day. A total daily dose of at least eight units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
Important Safety Information: MiniMed™ 630G System
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.